Table 2 Overall survival and clinicopathological variables in 85 patients with PDAC
From: Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma
Variables | Hazard ratio (95% CI) | p-value |
|---|---|---|
Univariate analysis | ||
Age (< 65 vs ≥65) | 0.98 (0.59–1.62) | .94 |
Gender (male vs. female) | 1.13 (0.68–1.88) | .65 |
Tumor size (< 2 cm vs. ≥ 2 cm) | 2.11 (1.07–4.16) | .03 |
Stage (I/II vs. III/IV) | 0.74 (0.44–1.26) | .28 |
Grade (low vs. high) | 1.84 (1.11–3.05) | .02 |
PNI | 1.18 (0.70–2.01) | .54 |
LVI | 1.46 (0.90–2.40) | .13 |
LN metastasis | 1.31 (0.77–2.21) | .32 |
HNF-1B (negative vs. positive) | 1.34 (0.70–2.57) | .38 |
No neoadjuvant | 1.14 (0.41–1.14) | .80 |
Multivariate analysis | ||
Tumor size (< 2 cm vs. ≥ 2 cm) | 2.10 (1.06–4.16) | .03 |
Grade (low vs. high) | 1.83 (1.10–3.06) | .02 |